Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
May 27, 2020
Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies
May 22, 2020
Global Cancer Antibody Drug Conjugate Market: A US$13 Billion Opportunity
Apr 28, 2020
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR(TM) GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
Apr 03, 2020
Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Mar 31, 2020
Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Feb 27, 2020
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
Feb 26, 2020
Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
Feb 18, 2020
Global ADC Linker & Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience
Feb 18, 2020
Antibody Drug Conjugates (ADCs)-Linker and Conjugation Technologies Market, 2019-2030
Feb 04, 2020
Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancers
Dec 09, 2019
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Dec 04, 2019
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia
Nov 14, 2019
FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
Nov 06, 2019
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Oct 23, 2019
Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates
Aug 06, 2019
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
Jul 10, 2019
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
Jun 20, 2019
Gracell Data on Multi-center Investigation of FasT CAR-19 Therapy Shows Positive First Impact in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia